AU2008269577B2 - Fused thiazole derivatives as kinase inhibitors - Google Patents

Fused thiazole derivatives as kinase inhibitors Download PDF

Info

Publication number
AU2008269577B2
AU2008269577B2 AU2008269577A AU2008269577A AU2008269577B2 AU 2008269577 B2 AU2008269577 B2 AU 2008269577B2 AU 2008269577 A AU2008269577 A AU 2008269577A AU 2008269577 A AU2008269577 A AU 2008269577A AU 2008269577 B2 AU2008269577 B2 AU 2008269577B2
Authority
AU
Australia
Prior art keywords
methyl
alkyl
dimethyl
morpholin
thiazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008269577A
Other languages
English (en)
Other versions
AU2008269577A1 (en
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile Crepy
Anne Marie Foley
Richard Jeremy Franklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by UCB SA filed Critical UCB SA
Priority claimed from PCT/GB2008/002194 external-priority patent/WO2009001089A1/en
Publication of AU2008269577A1 publication Critical patent/AU2008269577A1/en
Application granted granted Critical
Publication of AU2008269577B2 publication Critical patent/AU2008269577B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008269577A 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors Ceased AU2008269577B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
AUPCT/GB2007/002390 2007-06-26
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors
PCT/GB2008/002194 WO2009001089A1 (en) 2007-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2008269577A1 AU2008269577A1 (en) 2008-12-31
AU2008269577B2 true AU2008269577B2 (en) 2012-12-20

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008269577A Ceased AU2008269577B2 (en) 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Country Status (20)

Country Link
US (3) US8242116B2 (enExample)
EP (2) EP2035436B1 (enExample)
CN (1) CN101687885B (enExample)
AT (1) ATE510840T1 (enExample)
AU (1) AU2008269577B2 (enExample)
CA (1) CA2692085C (enExample)
CO (1) CO6270229A2 (enExample)
CY (1) CY1114419T1 (enExample)
DK (1) DK2170906T3 (enExample)
EA (1) EA017187B1 (enExample)
ES (2) ES2365258T3 (enExample)
HR (1) HRP20130523T1 (enExample)
IL (1) IL202659A0 (enExample)
ME (1) ME01592B (enExample)
MX (1) MX2009013740A (enExample)
MY (1) MY148852A (enExample)
PL (1) PL2170906T3 (enExample)
PT (1) PT2170906E (enExample)
RS (1) RS52824B (enExample)
WO (1) WO2008001076A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
MX2010010975A (es) 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
MX2011008645A (es) 2009-02-17 2011-09-30 Vertex Pharma Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
EP2408744A1 (en) * 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US8410095B2 (en) 2009-05-20 2013-04-02 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
JP5746172B2 (ja) 2009-08-20 2015-07-08 カルス セラピューティクス リミテッド ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環化合物
EA019980B1 (ru) 2009-12-18 2014-07-30 Янссен Фармацевтика Нв БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR5
CN102666551B (zh) 2009-12-18 2014-12-10 詹森药业有限公司 作为mglur5受体的变构调节剂的双环噻唑
ES2575566T3 (es) 2010-06-15 2016-06-29 Bayer Intellectual Property Gmbh Nuevos derivados de arilamida orto-sustituidos
BR112013007056A2 (pt) 2010-10-01 2019-09-24 Basf Se compostos de imina
CA2814688A1 (en) * 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EA201390759A1 (ru) * 2010-11-24 2014-03-31 Экселиксис, Инк. БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
PT2688887E (pt) 2011-03-23 2015-07-06 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
IN2014CN04174A (enExample) 2011-12-22 2015-09-04 Novartis Ag
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
HRP20202008T1 (hr) 2013-03-14 2021-02-19 Epizyme, Inc. Inhibitori arginin-metiltransferaze i njihove uporabe
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016518336A (ja) 2013-03-14 2016-06-23 エピザイム，インコーポレイティド Ｐｒｍｔ１阻害剤としてのピラゾール誘導体およびその使用
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160257650A1 (en) * 2013-10-21 2016-09-08 Umicore Ag & Co. Kg Monoarylation of aromatic amines
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
WO2020056269A1 (en) 2018-09-13 2020-03-19 Stemline Therapeutics, Inc. Methods for treating centronuclear myopathy
NZ777871A (en) 2018-12-19 2024-11-29 Leo Pharma As Small molecule modulators of il-17
US12577217B2 (en) * 2019-01-08 2026-03-17 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitor
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
CO6270229A2 (es) 2011-04-20
CA2692085A1 (en) 2008-12-31
CA2692085C (en) 2015-10-13
US8338592B2 (en) 2012-12-25
PL2170906T3 (pl) 2013-08-30
CN101687885A (zh) 2010-03-31
IL202659A0 (en) 2010-06-30
AU2008269577A1 (en) 2008-12-31
MY148852A (en) 2013-06-14
ME01592B (me) 2014-09-20
ATE510840T1 (de) 2011-06-15
ES2365258T3 (es) 2011-09-27
US8710054B2 (en) 2014-04-29
EP2170906B1 (en) 2013-04-03
EA201000038A1 (ru) 2010-06-30
US20100137302A1 (en) 2010-06-03
ES2416364T3 (es) 2013-07-31
CY1114419T1 (el) 2016-08-31
EP2170906A1 (en) 2010-04-07
PT2170906E (pt) 2013-06-25
MX2009013740A (es) 2010-02-01
HRP20130523T1 (en) 2013-07-31
DK2170906T3 (da) 2013-06-24
CN101687885B (zh) 2012-08-22
US20110003785A1 (en) 2011-01-06
EP2035436B1 (en) 2011-05-25
US8242116B2 (en) 2012-08-14
EP2035436A1 (en) 2009-03-18
WO2008001076A1 (en) 2008-01-03
RS52824B (enExample) 2013-10-31
US20130079330A1 (en) 2013-03-28
EA017187B1 (ru) 2012-10-30

Similar Documents

Publication Publication Date Title
AU2008269577B2 (en) Fused thiazole derivatives as kinase inhibitors
AU2006239018B2 (en) Fused thiazole derivatives as kinase inhibitors
US20090264411A1 (en) Fused thiophene derivatives as mek inhibitors
WO2009153554A1 (en) Thieno-pyridine derivatives as mek inhibitors
WO2009071890A1 (en) Tricyclic kinase inhibitors
EP2432784A1 (en) Fused bicyclic pyrazole derivatives as kinase inhibitors
WO2009071895A1 (en) Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071888A1 (en) Pyrrolothiazoles as pi3-kinase inhibitors
US8168634B2 (en) Thiazole derivatives as kinase inhibitors
KR101577314B1 (ko) 키나제 억제제로서의 접합된 티아졸 유도체
HK1140756B (en) Fused thiazole derivatives as kinase inhibitors
WO2010146351A1 (en) Indolylmethyl-morpholine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired